Fadlo R. Khuri

84.3k citations

486 papers · 27.1k indexed · 6 hit papers · h-index 85

Molecular Biology top 0.1%
Oncology top 0.1%
Pulmonary and Respiratory Medicine top 0.2%
Cancer Research top 0.1%
Genetics top 0.5%

Co-authors: Shi‐Yong Sun Dong M. Shin Taofeek K. Owonikoko Ping Yue Suresh S. Ramalingam Haian Fu Waun Ki Hong J. Jack Lee
Topics: Lung Cancer Treatments and Mutations (106 papers)Lung Cancer Research Studies (72 papers)Head and Neck Cancer Studies (61 papers)
Cited by: Otorhinolaryngology Oncology Cancer Research
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences The Lancet
Partner nations: United States China Lebanon

In The Last Decade

Fadlo R. Khuri

476 papers receiving 26.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

2000 858 citations Fadlo R. Khuri, Waun Ki Hong et al. profile →
Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition

2005 682 citations Shi-Yong Sun, Xuerong Wang et al. Cancer Research profile →
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

2009 618 citations Sagar Lonial, Fadlo R. Khuri et al. profile →
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

2017 582 citations Rathi N. Pillai, Gabriel Sica et al. profile →
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

2013 486 citations Fadlo R. Khuri, Jonathan J. Beitler et al. profile →
Lung cancer: New biological insights and recent therapeutic advances

2011 391 citations Suresh S. Ramalingam, Taofeek K. Owonikoko et al. profile →

Peers

Countries citing papers authored by Fadlo R. Khuri

Since Specialization

Citations

This map shows the geographic impact of Fadlo R. Khuri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fadlo R. Khuri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fadlo R. Khuri more than expected).

Fields of papers citing papers by Fadlo R. Khuri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fadlo R. Khuri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fadlo R. Khuri. The network helps show where Fadlo R. Khuri may publish in the future.

Co-authorship network of co-authors of Fadlo R. Khuri

This figure shows the co-authorship network connecting the top 25 collaborators of Fadlo R. Khuri. A scholar is included among the top collaborators of Fadlo R. Khuri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fadlo R. Khuri. Fadlo R. Khuri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck 2020 ·Clinical Cancer Research ·Dong M. Shin,Sreenivas Nannapaneni,Mihir R. Patel,Qiuying Shi,Yuan Liu,Zhengjia Chen,Amy Y. Chen,Mark W. El‐Deiry,Jonathan J. Beitler,Conor Steuer,Steven M. Roser,Adam M. Klein,Taofeek K. Owonikoko,Suresh S. Ramalingam,Fadlo R. Khuri,Zhuo G. Chen,Nabil F. Saba	13
2	Maintaining Glycogen Synthase Kinase-3 Activity Is Critical for mTOR Kinase Inhibitors to Inhibit Cancer Cell Growth 2014 ·Cancer Research ·Junghui Koo,Ping Yue,Anthony A. Gal,Fadlo R. Khuri,Shi‐Yong Sun	37
3	Cables1 Complex Couples Survival Signaling to the Cell Death Machinery 2014 ·Cancer Research ·Zhi Shi,Hae Ryoun Park,Yuhong Du,Zijian Li,Kejun Cheng,Shi‐Yong Sun,Zenggang Li,Haian Fu,Fadlo R. Khuri	33
4	Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma 2014 ·Molecular Cancer Therapeutics ·Ning Jiang,Dongsheng Wang,Zhongliang Hu,Hyung Ju C. Shin,Guoqing Qian,Mohammad Aminur Rahman,Hongzheng Zhang,A.R.M. Ruhul Amin,Sreenivas Nannapaneni,Xiao‐Jing Wang,Zhengjia Chen,Gabriela Garcia,Gavin MacBeath,Dong M. Shin,Fadlo R. Khuri,Jun Ma,Zhuo G. Chen,Nabil F. Saba	50
5	Class I HDACs Are Mediators of Smoke Carcinogen–Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer 2014 ·Cancer Prevention Research ·(unknown),(unknown),(unknown),Hyunseok Kang,Suresh S. Ramalingam,Madhusmita Behera,Khanjan Gandhi,Jeanne Kowalski,Gabriel Sica,Fadlo R. Khuri,Paula M. Vertino,Johann C. Brandes	32
6	CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC 2013 ·Clinical Cancer Research ·Rathi N. Pillai,(unknown),Gabriel Sica,Shaojin You,Ge Li,Dana Nickleach,Yuan Liu,Vijay Varma,Dacian Bonta,James G. Herman,(unknown),(unknown),Suresh S. Ramalingam,Taofeek K. Owonikoko,Fadlo R. Khuri,Johann C. Brandes	22
7	Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer 2013 ·Cancer Research ·Dongkyoo Park,Andrew T. Magis,Rui Li,Taofeek K. Owonikoko,Gabriel Sica,Shi‐Yong Sun,Suresh S. Ramalingam,Fadlo R. Khuri,Walter J. Curran,Xingming Deng	59
8	mTOR Complex 2 Is Involved in Regulation of Cbl-Dependent c-FLIP Degradation and Sensitivity of TRAIL-Induced Apoptosis 2013 ·Cancer Research ·Liqun Zhao,Ping Yue,Fadlo R. Khuri,Shi‐Yong Sun	35
9	The Novel Akt Inhibitor API-1 Induces c-FLIP Degradation and Synergizes with TRAIL to Augment Apoptosis Independent of Akt Inhibition 2012 ·Cancer Prevention Research ·Bo Li,Hui Ren,Ping Yue,Mingwei Chen,Fadlo R. Khuri,Shi‐Yong Sun	15
10	Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention 2012 ·Clinical Cancer Research ·Michelle A.T. Hildebrandt,Scott M. Lippman,Carol J. Etzel,Edward Kim,J. Jack Lee,Fadlo R. Khuri,Margaret R. Spitz,Reuben Lotan,Waun Ki Hong,Xifeng Wu	37
11	Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients 2011 ·Cancer Prevention Research ·J. Jack Lee,Xifeng Wu,Michelle A.T. Hildebrandt,Hushan Yang,Fadlo R. Khuri,Edward Kim,Jian Gu,Yuanqing Ye,Reuben Lotan,Margaret R. Spitz,Waun Ki Hong	26
12	The NEDD8-Activating Enzyme Inhibitor, MLN4924, Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells 2011 ·Molecular Cancer Therapeutics ·Liqun Zhao,Ping Yue,Sagar Lonial,Fadlo R. Khuri,Shi‐Yong Sun	35
13	Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy 2009 ·Cancer Research ·Lei Fu,Young‐Ae Kim,Xuerong Wang,Xiaoyun Wu,Ping Yue,Sagar Lonial,Fadlo R. Khuri,Shi‐Yong Sun	129
14	Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism 2009 ·Molecular Cancer Therapeutics ·Heath A. Elrod,Ping Yue,Fadlo R. Khuri,Shi‐Yong Sun	13
15	The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor–induced apoptosis 2008 ·Molecular Cancer Therapeutics ·Shruti M. Raja,Shuzhen Chen,Ping Yue,Timothy M. Acker,Benjamin Lefkove,Jack L. Arbiser,Fadlo R. Khuri,Shi‐Yong Sun	42
16	CAAT/Enhancer Binding Protein Homologous Protein–Dependent Death Receptor 5 Induction Is a Major Component of SHetA2-Induced Apoptosis in Lung Cancer Cells 2008 ·Cancer Research ·(unknown),Shuzhen Chen,Ping Yue,Wei Zou,Doris M. Benbrook,Shengquan Liu,Thanh C. Le,K. Darrell Berlin,Fadlo R. Khuri,Shi-Yong Sun	44
17	The Tumor Suppressor LKB1 Regulates Lung Cancer Cell Polarity by Mediating cdc42 Recruitment and Activity 2008 ·Cancer Research ·Shumin Zhang,Katherine Schafer-Hales,Fadlo R. Khuri,Wei Zhou,Paula M. Vertino,Adam I. Marcus	81
18	The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells 2007 ·Cancer Research ·Liu X,Ping Yue,Shuzhen Chen,Liping Hu,Sagar Lonial,Fadlo R. Khuri,Shi‐Yong Sun	141
19	The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway 2007 ·Molecular Cancer Therapeutics ·Heath A. Elrod,Yidan Lin,Ping Yue,Xuerong Wang,Sagar Lonial,Fadlo R. Khuri,Shi‐Yong Sun	79
20	Cellular FLICE-Inhibitory Protein Down-regulation Contributes to Celecoxib-Induced Apoptosis in Human Lung Cancer Cells 2006 ·Cancer Research ·Liu X,Ping Yue,Axel H. Schönthal,Fadlo R. Khuri,Shi‐Yong Sun	64

About Fadlo R. Khuri

Fadlo R. Khuri is a scholar working on Otorhinolaryngology, Oncology and Cancer Research, having authored 486 papers that have together received 27.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (106 papers), Lung Cancer Research Studies (72 papers) and Head and Neck Cancer Studies (61 papers). The work is most often cited by research in Otorhinolaryngology (2.1k citations), Oncology (9.9k citations) and Cancer Research (4.5k citations). Fadlo R. Khuri has collaborated with scholars based in United States, China and Lebanon. Frequent co-authors include Shi‐Yong Sun, Dong M. Shin, Taofeek K. Owonikoko, Ping Yue, Suresh S. Ramalingam, Haian Fu, Waun Ki Hong, J. Jack Lee, Roy S. Herbst and Liu X. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact